Hydroxyurea use does not impact development of serious COVID-19 or need for hospitalization in children or adults
WEDNESDAY, July 14, 2021 (HealthDay News) — A history of severe pain episodes and coexisting organ conditions may increase the risk for severe COVID-19 illness and hospitalization in individuals living with sickle cell disease (SCD), according to a study published online July 1 in Blood Advances.
Lana Mucalo, M.D., from the Medical College of Wisconsin in Milwaukee, and colleagues established the SECURE-SCD Registry to collect data on patients with SCD and COVID-19 illness to understand the impact of severe acute respiratory syndrome coronavirus 2 infection on this population. The analysis included 750 cases of COVID-19 illness in patients with SCD that were reported to the registry as of March 23, 2021.
The researchers found that history of pain (relative risk [RR], 2.15) and SCD heart/lung comorbidities (RR, 1.61) were risk factors for COVID-19 hospitalization in children, while history of pain (RR, 1.78) was a risk factor for hospitalization in adults. Similarly, the risk for developing serious COVID-19 illness was higher in children with a history of pain (RR, 3.09), SCD heart/lung comorbidities (RR, 1.76), and SCD renal comorbidities (RR, 3.67). For adults, a history of pain remained a risk factor (RR, 1.94). In children, history of pain and SCD renal comorbidities increased the risk for pain during COVID-19. For adults, an increased risk for pain during COVID-19 was associated with a history of pain, SCD heart/lung comorbidities, and female sex. There was no effect seen for hydroxyurea on hospitalization and COVID-19 severity.
“This study tells us that all individuals with sickle cell disease are not at equal levels of risk,” Mucalo said in a statement.
~16 Percent of COVID Cases Develop Postacute Sequelae of SARS-CoV-2
Low Placental Growth Factor Predicts Early-Onset Preeclampsia in Patients With SCD
Majority of Patients in ED With Sickle Cell Crisis Not Triaged Appropriately
Timely Opioid Administration Cuts Hospitalizations for Pediatric Sickle Cell Crises
Distinct Characteristics ID"d for Patients With Rheumatoid Conditions, Opioid Use Disorder
People Using Illicitly Sourced Fentanyl Face Worse Outcomes Than Medically Sourced Users
CDC: Buprenorphine Treatment Differs in Urban, Rural Areas
Adding Cognitive Behavioral Therapy, Self-Management Does Not Improve Opioid Taper Success